|
1
|
Ouyang Q, Tandon R, Goh KL, Ooi CJ, Ogata
H and Fiocchi C: The emergence of inflammatory bowel disease in the
Asian Pacific region. Curr Opin Gastroenterol. 21:408–413.
2005.PubMed/NCBI
|
|
2
|
Jiang Y, Xia B, Jiang L, et al:
Association of CTLA-4 gene microsatellite polymorphism with
ulcerative colitis in Chinese patients. Inflamm Bowel Dis.
12:369–373. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vermeire S: Genetic susceptibility and
application of genetic testing in clinical management of
inflammatory bowel disease. Aliment Pharmacol Ther. 24(Suppl 3):
2–10. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Weaver CT, Harrington LE, Mangan PR,
Gavrieli M and Murphy KM: Th17: an effector CD4 T cell lineage with
regulatory T cell ties. Immunity. 24:677–688. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Harrington LE, Mangan PR and Weaver CT:
Expanding the effector CD4 T-cell repertoire: the Th17 lineage.
Curr Opin Immunol. 18:349–356. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Podolsky DK: Inflammatory bowel disease. N
Eng J Med. 347:417–429. 2002. View Article : Google Scholar
|
|
7
|
Iwakura Y and Ishigame H: The IL-23/IL-17
axis in inflammation. J Clin Invest. 116:1218–1222. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Park H, Li Z, Yang XO, et al: A distinct
lineage of CD4 T cells regulates tissue inflammation by producing
interleukin 17. Nat Immunol. 6:1133–1141. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Veldhoen M, Hocking RJ, Atkins CJ,
Locksley RM and Stockinger B: TGFbeta in the context of an
inflammatory cytokine milieu supports de novo differentiation of
IL-17-producing T cells. Immunity. 24:179–189. 2006. View Article : Google Scholar
|
|
10
|
Langrish CL, Chen Y, Blumenschein WM, et
al: IL-23 drives a pathogenic T cell population that induces
autoimmune inflammation. J Exp Med. 201:233–240. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yamada H: Th17 cells and human arthritic
diseases. Nihon Rinsho Meneki Gakkai Kaishi. 33:214–221. 2010.(In
Japanese).
|
|
12
|
Hue S, Ahern P, Buonocore S, et al:
Interleukin-23 drives innate and T cell- tmediated intestinal
inflammation. J Exp Med. 203:2473–2483. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Blaschitz C and Raffatellu M: Th17
cytokines and the gut mucosal barrier. J Clin Immunol. 30:196–203.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang Z, Zheng M, Bindas J,
Schwarzenberger P and Kolls JK: Critical role of IL-17 receptor
signaling in acute TNBS-induced colitis. Inflamm Bowel Dis.
12:382–388. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Becker C, Dornhoff H, Neufertet C, et al:
Cutting edge: IL-23 Eross-rugulates IL-12 production in T
cell-dependent experimental colitis. J Immunol. 177:2760–2764.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Davidson NJ, Leach MW, Fort MM, et al: T
helper cell 1-type CD4+ T cells, but not B cells,
mediate colitis in interleukin 10-deficient mice. J Exp Med.
184:241–225. 1996.PubMed/NCBI
|
|
17
|
Fossiez F, Banchereau J, Murray R, Van
Kooten C, Garrone P and Lebecque S: Interleukin-17. Int Rev
Immunol. 16:541–551. 1998. View Article : Google Scholar
|
|
18
|
Batten M, Li J, Yi S, et al:
Interleukin-27 limits autoimmune encephalomyelitis by suppressing
the development of interleukin 17-producing T cells. Nat Immunol.
7:929–936. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Elson CO, Cong Y, Weaver CT, et al:
Monoclonal anti-interleukin 23 reverses active colitis in a T
cell-mediated model in mice. Gastroenterology. 132:2359–2370. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Targan SR and Karp LC: Defects in mucosal
immunity leading to ulcerative colitis. Immunol Rev. 206:296–305.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Reddy KP, Markowitz JE, Ruchelli ED,
Baldassano RN and Brown KA: Lamina propria and circulating
interleukin-8 in newly and previously diagnosed pediatric
inflammatory bowel disease patients. Dig Dis Sci. 52:365–372. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hong DS, Angelo LS and Kurzrock R:
Interleukin-6 and its receptor in cancer: implications for
translational therapeutics. Cancer. 110:1911–1928. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Van Assche G, Magdelaine-Beuzelin C,
D’Haens G, et al: Withdrawal of immunosuppression in Crohns disease
treated with seheduled infliximab maintaince: a randomized trial.
Gastroenterology. 134:1861–1868. 2008.PubMed/NCBI
|
|
24
|
Orlando A, Mocciaro F, Civitavecchia G,
Scimeca D and Cottone M: Minimizing infliximab toxicity in the
treatment of inflammatory bowel disease. Dig Liver Dis. 40(Suppl
2): S236–S246. 2008. View Article : Google Scholar : PubMed/NCBI
|
